A factor in the development of sarcopenia/frail in patients with chronic kidney disease

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K17718
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53040:Nephrology-related
• Research Institution: Juntendo University
• Principal Investigator: Wakabayashi Keichi 順天堂大学, 医学部, 助教 (60748565)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: CKD / サルコペニア / フレイル / AGEs / 血管内皮障害

Outline of Final Research Achievements

Sarcopenia/frailty is frequent in patients with CKD. AGEs, which are urinary toxins, induce oxidative stress and inflammation, and are involved in organ damage via endothelial damage factors such as ADMA. In this study, we investigated the relationship between AGEs and sarcopenia/frailty in CKD. In the CKD model animals, AGE accumulation in the gastrocnemius muscle was observed, and morphological changes, loss of capillaries, and mitochondrial dysfunction were observed in the muscles. These changes were ameliorated by administration of AGE aptamers. The results suggest that AGEs may be a new therapeutic target to inhibit the onset and progression of sarcopenia through endothelial function.

Free Research Field

血管内皮障害

Academic Significance and Societal Importance of the Research Achievements

CKD患者における、サルコペニア/フレイルの病態及びその分子機序を明らかとすることは、CKD患者のQOL/生命予後/健康寿命の改善に繋がるだけでなく、医療費削減にも繋がり、社会的に大きな意味をもつと考える。
本研究で、AGEがCKDにおけるサルコペニア/ フレイルの重要な発症因子であることが明らかとなった。AGEによる内皮障害を制御することで、サルコペニア/フレイルの発症・進展を抑制する新たな治療法の開発へ繋がる。